Beddow Capital Management Inc. Grows Position in Organon & Co. (NYSE:OGN)

Beddow Capital Management Inc. boosted its position in shares of Organon & Co. (NYSE:OGN) by 38.8% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 306,675 shares of the company’s stock after acquiring an additional 85,775 shares during the quarter. Organon & Co. makes up about 2.4% of Beddow Capital Management Inc.’s portfolio, making the stock its 18th biggest position. Beddow Capital Management Inc.’s holdings in Organon & Co. were worth $5,867,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in OGN. State Board of Administration of Florida Retirement System increased its holdings in Organon & Co. by 3.7% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 277,929 shares of the company’s stock worth $5,225,000 after purchasing an additional 9,899 shares during the period. Mitsubishi UFJ Trust & Banking Corp raised its holdings in shares of Organon & Co. by 20.0% in the first quarter. Mitsubishi UFJ Trust & Banking Corp now owns 427,575 shares of the company’s stock valued at $7,910,000 after acquiring an additional 71,258 shares in the last quarter. Vanguard Group Inc. lifted its stake in Organon & Co. by 0.6% in the first quarter. Vanguard Group Inc. now owns 30,789,850 shares of the company’s stock worth $578,849,000 after acquiring an additional 192,613 shares during the period. O Shaughnessy Asset Management LLC grew its holdings in Organon & Co. by 187.1% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 39,758 shares of the company’s stock worth $747,000 after acquiring an additional 25,909 shares in the last quarter. Finally, UniSuper Management Pty Ltd purchased a new position in Organon & Co. during the 1st quarter valued at about $982,000. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Price Performance

NYSE:OGN opened at $15.11 on Tuesday. The firm has a market cap of $3.89 billion, a price-to-earnings ratio of 3.00, a PEG ratio of 0.70 and a beta of 0.84. The firm’s fifty day moving average is $18.04 and its two-hundred day moving average is $19.92. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. Organon & Co. has a one year low of $10.84 and a one year high of $23.10.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). The firm had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.56 billion. Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The business’s quarterly revenue was up 4.1% on a year-over-year basis. During the same period last year, the company posted $0.78 earnings per share. Research analysts expect that Organon & Co. will post 3.89 EPS for the current year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Shareholders of record on Tuesday, November 12th will be given a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 7.41%. The ex-dividend date of this dividend is Tuesday, November 12th. Organon & Co.’s dividend payout ratio is presently 22.22%.

Analyst Ratings Changes

Several equities analysts recently issued reports on OGN shares. Evercore ISI raised shares of Organon & Co. to a “strong-buy” rating in a report on Wednesday, September 18th. JPMorgan Chase & Co. cut shares of Organon & Co. from a “neutral” rating to an “underweight” rating and lifted their target price for the stock from $18.00 to $20.00 in a research note on Friday, September 6th.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.